invest1 publisher
A Bristol Myers Phase 1 will price Orum's degrader platform in February 2027
Orum halted an earlier antibody-degrader conjugate in April last year after a death and unexplained liver toxicity. The candidate Bristol Myers is testing in leukemia sits on the same platform, and a second in-house candidate uses the same degrader.
Publishers:en.sedaily.com
Reality
- Evidence32
- Adoption40
- Hype gap+35
- Incentives70
- Confidence45